請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/67015
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳明汝 | |
dc.contributor.author | Shun-Yu Huang | en |
dc.contributor.author | 黃舜瑜 | zh_TW |
dc.date.accessioned | 2021-06-17T01:17:18Z | - |
dc.date.available | 2022-08-24 | |
dc.date.copyright | 2017-08-24 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-08-14 | |
dc.identifier.citation | 何懿芳。2013。微膠囊化對 Lactobacillus kefiranofaciens M1 及 Lactobacillus mali APS1 耐熱及抗結腸炎機能性之影響。臺灣大學動物科學技術學研究所。碩士論文。
沈澤臻。2014。藉由小鼠與犬隻模式探討 Lactobacillus kefiranofaciens M1 於異位性皮膚炎之研究。臺灣大學動物科學技術學研究所。碩士論文。 魏士弘。2014。篩選可刺激類升糖素胜肽-1 分泌之益生菌及探討其減緩高血糖症之研究。臺灣大學動物科學技術學研究所。碩士論文。 Alam, C., S. Valkonen, V. Palagani, J. Jalava, E. Eerola, and Hänninen, A. 2010. Inflammatory tendencies and overproduction of IL-17 in the colon of young NOD mice are counteracted with diet change. Diabetes 59: 2237-2246. Anderson, R. C., A. L. Cookson, W. C. McNabb, Z. Park, M. J. McCann, W. J. Kelly, and N.C. Roy. 2010. Lactobacillus plantarum MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formation. BMC Microbiology 10: 316. Arata, M., L. Bruno, C. Pastorale, F. Pagliero, and J. C. Basabe. 2001. Effect of modified diabetic splenocytes on mice injected with splenocytes from multiple low-dose streptozotocin diabetic donors. Experimental Biology and Medicine 226: 898–905 Asseman, C., S. Mauze, M. W. Leach, R. L. Coffman, and F. Powrie. 1999. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. Journal of Experimental Medicine 190: 995-1004. Atkinson, M. A., and G. S. Eisenbarth. 2001. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. The Lancet 358: 221-229. Beales, P., R. Elliott, S. Flohe, J. Hill, H. Kolb, P. Pozzilli, G. S. Wang, H. Wasmuth, and F. Scott. 2002. A multi-centre, blinded international trial of the effect of A1 and A2 ß-casein variants on diabetes incidence in two rodent models of spontaneous type 1 diabetes. Diabetologia 45: 1240-1246. Belle, T. L., K. T. Coppieters, and M. G.Von Herrath. 2011. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiological Reviews 91: 79-118. Borchers, A. T., C. Selmi, F. J. Meyers, C. L. Keen, and M. E. Gershwin. 2009. Journal of Gastroenterology 44: 26-46. Bottini, N., L. Musumeci, A. Alonso, S. Rahmouni, K. Nika, Rostamkhani M., J. MacMurray, G. F. Meloni, P. Lucarelli, and M. Pellecchia. 2004. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nature Genetics 36: 337-338. Brugman, S., F. Klatter, J. Visser, A. Wildeboer-Veloo, H. Harmsen, J. Rozing, and N. Bos. 2006. Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-prone rat. Is the gut flora involved in the development of type 1 diabetes? Diabetologia 49: 2105-2108. Brussels, B. International Diabetes Federation. 2015.IDF Diabetes Atlas, 7th edn. Caballero-Franco, C. K., C. Keller De Simone, and K. Chadee 2007. The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. American Journal of Physiology-Gastrointestinal and Liver Physiology 292: G315-G322. Calcinaro, F., S. Dionisi, M. Marinaro, P. Candeloro, V. Bonato, S. Marzotti, R. Corneli, E. Ferretti, A. Gulino, and F. Grasso. 2005. Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia 48: 1565-1575. Carratù, R., M. Secondulfo, L. de Magistris, D. Iafusco, A. Urio, M.G. Carbone, G. Pontoni, M. Cartenì, and F. Prisco. 1999. Altered intestinal permeability to mannitol in diabetes mellitus type I. Journal of Pediatric Gastroenterology and Nutrition 28: 264-269. Chen, Y. P., P. J. Hsiao, W. S. Hong, T. Y. Dai, and M. J. Chen. 2012. Lactobacillus kefiranofaciens M1 isolated from milk kefir grains ameliorates experimental colitis in vitro and in vivo. Journal of Dairy Science 95: 63-74. Christensen, H.R., H. Frøkiær, and J.J. Pestka. 2002. Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. The Journal of Immunology 168: 171-178. Dahlquist, G., G. Frisk, S. Ivarsson,L Svanberg, M. Forsgren, and H. Diderholm. 1995. Indications that maternal coxsackie B virus infection during pregnancy is a risk factor for childhood-onset IDDM. Diabetologia 38: 1371-1373. Dahlquist, G. G., S. Ivarsson, B. Lindberg, and M. Forsgren. 1995. Maternal enteroviral infection during pregnancy as a risk factor for childhood IDDM: a population-based case-control study. Diabetes 44: 408-413. Dorman, J. S., and C. H. Bunker. 2000. HLA-DQ locus of the human leukocyte antigen complex and type 1 diabetes mellitus: a HuGE review. Epidemiologic Reviews 22: 218-227. Dotta, F., S. Censini, A. G. van Halteren, L. Marselli, M. Masini, S. Dionisi, F. Mosca, U. Boggi, A. O. Muda, and S. Del Prato. 2007. Coxsackie B4 virus infection of β cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proceedings of the National Academy of Sciences 104: 5115-5120. Drescher, K. M., K. Kono, S. Bopegamage, S. D. Carson, and S. Tracy. 2004. Coxsackievirus B3 infection and type 1 diabetes development in NOD mice: insulitis determines susceptibility of pancreatic islets to virus infection. Virology 329: 381-394. Dubernet, S., N. Desmasures, and M. Guéguen. 2002. A PCR-based method for identification of lactobacilli at the genus level. FEMS Microbiology Letters 214: 271-275. Elias, D., H. Prigozin, N. Polak, M. Rapoport, A. W. Lohse, and I. R. Cohen. 1994. Autoimmune diabetes induced by the beta-cell toxin STZ. Immunity to the 60-kDa heat shock protein and to insulin. Diabetes 43: 992–998. Flohe, S., H. Wasmuth, J. Kerad, P. Beales, P. Pozzilli, R. Elliott, J. Hill, F. Scott, and H. Kolb. 2003. A wheat-based, diabetes-promoting diet induces a Th1-type cytokine bias in the gut of NOD mice. Cytokine 21: 149-154. Gelber, C., L. Paborsky, S. Singer, D. McAteer, R. Tisch, C. Jolicoeur, and C. G. Fathman. 1994. Isolation of nonobese diabetic mouse T-cells that recognize novel autoantigens involved in the early events of diabetes. Diabetes 43: 33-39. Ghosh, S., D. Van Heel, and R. Playford. 2004. Probiotics in inflammatory bowel disease: is it all gut flora modulation? Gut 53: 620-622. Gionchetti, P., F. Rizzello, A. Venturi, P. Brigidi, D. Matteuzzi, G. Bazzocchi, G. Poggioli, M. Miglioli, and M. Campieri. 2000. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119: 305-309. Gorbach, S., T.-W Chang, and B. Goldin. 1987. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. The Lancet 330: 1519. Groschwitz, K. R., and S. P. Hogan. 2009. Intestinal barrier function: molecular regulation and disease pathogenesis. Journal of Allergy and Clinical Immunology 124: 3-20. Christensen, H. R., H. Frøkiær, and J. J. Pestka. 2002. Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. The Journal of Immunology 168: 171-178. Hadisaputro, S., R. R. Djokomoeljanto and M. H. Soesatyo. 2012. The effects of oral plain kefir supplementation on proinflammatory cytokine properties of the hyperglycemia Wistar rats induced by streptozotocin. Acta Med Indones 44(100): e4. Hänninen, A., R. Nurmela, M. Maksimow, J. Heino, S. Jalkanen, and C. Kurts. 2007. Islet β-cell-specific T cells can use different homing mechanisms to infiltrate and destroy pancreatic islets. The American Journal of Pathology 170: 240-250. Heikki, H., H. Merja, K. Mikael, L. Maria, V. Paula, K. Jukka, K. Pentti, R. Merja, and L. Pauli. 1995. A prospective study of the role of coxsackie B and other enterovirus infections in the pathogenesis of IDDM. Diabete 44: 652-657. Herrath, M., S. Sanda, and K. Herold. 2007. Type 1 diabetes as a relapsing–remitting disease?. Nature Reviews. Immunology 7: 988-994. Holmes, J. L., C. M. Van Itallie, J. E. Rasmussen, and J. M. Anderson. 2006. Claudin profiling in the mouse during postnatal intestinal development and along the gastrointestinal tract reveals complex expression patterns. Gene Expression Patterns 6: 581-588. Honkanen, J., J. K. Nieminen, R. Gao, K. Luopajarvi, H. M. Salo, J. Ilonen, and O.Vaarala. 2010. IL-17 immunity in human type 1 diabetes. The Journal of Immunology 185: 1959-1967. Horwitz, M. S., C. Fine, A. Ilic, and N. Sarvetnick. 2001. Requirements for viral-mediated autoimmune diabetes: β-cell damage and immune infiltration. Journal of Autoimmunity 16: 211-217. Ho, S. T., Y. T. Tung, Y. J. Wu, C. C. Lin, and J. H. Wu. 2015. Immune-regulatory activity of methanolic extract of Acacia confusa heartwood and melanoxetin isolated from the extract. Holzforschung 69: 645-652. Hubatsch, I., E. G. Ragnarsson, and P. Artursson. 2007. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nature Protocols 2: 2111-2119. Isolauri, E., T. Rautanen, M. Juntunen, P. Sillanaukee, and T. Koivula. 1991. A human Lactobacillus strain (Lactobacillus casei sp. strain GG) promotes recovery from acute diarrhea in children. Pediatrics 88: 90-97. Jeon, S.G., H. Kayama, Y. Ueda, T. Takahashi, T. Asahara, H. Tsuji, N.M. Tsuji, H. Kiyono, J.S. Ma, and T. Kusu. 2012. Probiotic Bifidobacterium breve induces IL-10-producing Tr1 cells in the colon. PLoS Pathogens 8, e1002714. Kim, Y., S. H. Kim, K. Y. Whang, Y. J. Kim, and S. Oh. 2008. Inhibition of Escherichia coli O157: H7 attachment by interactions between lactic acid bacteria and intestinal epithelial cells. Journal of Microbiology and Biotechnology 18: 1278-1285. Knip, M., R. Veijola, S. M. Virtanen, H. Hyöty, O. Vaarala, and H.K. Åkerblom. 2005. Environmental triggers and determinants of type 1 diabetes. Diabetes 54: 125-136. Kostraba, J. N., K .J. Cruickshanks, J. Lawler-Heavner, L. F. Jobim, M. J. Rewers, E.C. Gay, H. P. Chase, G. Klingensmith, and R. F. Hamman. 1993. Early exposure to cow's milk and solid foods in infancy, genetic predisposition, and risk of IDDM. Diabetes 42: 288-295. Kikuchi, E., Y. Miyamoto, S. Narushima, and K. Itoh. 2002. Design of species‐specific primers to identify 13 species of Clostridium harbored in human intestinal tracts. Microbiology and Immunology 46: 353-358. Kyvik, K. O., A. Green, and H. Beck-Nielsen. 1995. Concordance rates of insulin dependent diabetes mellitus: a population based study of young Danish twins. British Medical Journal 311: 913-917. Lau, K., P. Benitez, A. Ardissone, T. D. Wilson, E. L. Collins, G. Lorca, N. Li, D. Sankar, C. Wasserfall, and J. Neu. 2011. Inhibition of type 1 diabetes correlated to a Lactobacillus johnsonii N6. 2-mediated Th17 bias. The Journal of Immunology 186: 3538-3546. Lebeer, S., J. Vanderleyden, and S. C. De Keersmaecker. 2010. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nature Reviews. Microbiology 8: 171-184. Lipscomb, M. F., and B. J. Masten. 2002. Dendritic cells: immune regulators in health and disease. Physiological reviews 82: 97-130. Leiter, E. H. 1982. Multiple low-dose streptozotocin-induced hyperglycemia and insulitis in C57BL mice: influence of inbred background, sex, and thymus. Proceedings of the National Academy of Sciences. 79:630-634. Like, A.A., and A.A. Rossini. 1976. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science. 193:415–417. Littorin, B., P. Blom, A. Schölin, H. Arnqvist, G. Blohme, J. Bolinder, A. Ekbom-Schnell, J.W. Eriksson, S. Gudbjörnsdottir, and L. Nyström. 2006. Lower levels of plasma 25-hydroxyvitamin D among young adults at diagnosis of autoimmune type 1 diabetes compared with control subjects: results from the nationwide Diabetes Incidence Study in Sweden (DISS). Diabetologia 49: 2847-2852. Madsen, K., A. Cornish, P. Soper, C. McKaigney, H. Jijon, C. Yachimec, J. Doyle, L. Jewell, and C. De Simone. 2001. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 121: 580-591. Moran, A., B. Bundy, D. J. Becker, L. A. DiMeglio, S. E. Gitelman, R. Goland, C. J. Greenbaum, K. C. Herold, J. B. Marks, P. Raskin et al. AIDA Study Group. 2013. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. The Lancet 381: 1905-1915. Matsuda, K., H. Tsuji, T. Asahara, K. Matsumoto, T. Takada, and K. Nomoto. 2009. Establishment of an analytical system for the human fecal microbiota, based on reverse transcription-quantitative PCR targeting of multicopy rRNA molecules. Applied and Environmental Microbiology 75: 1961-1969. Mathieu, C., C. Gysemans, A. Giulietti, and R. Bouillon. 2005. Vitamin D and diabetes. Diabetologia 48: 1247-1257. Mathieu, C., M. Waer, J. Laureys, O. Rutgeerts, and R. Bouillon, 1994. Prevention of autoimmune diabetes in NOD mice by 1, 25 dihydroxyvitamin D3. Diabetologia 37: 552-558. Matsuzaki, T., Y. Nagata, S. Kado, K. Uchida, I. Kato, S. Hashimoto, and T. Yokokura. 1997. Prevention of onset in an insulin‐dependent diabetes mellitus model, NOD mice, by oral feeding of Lactobacillus casei. Apmis 105: 643-649. Meddings, J., J. Jarand, S. Urbanski, J. Hardin, and D. Gall. 1999. Increased gastrointestinal permeability is an early lesion in the spontaneously diabetic BB rat. American Journal of Physiology-Gastrointestinal and Liver Physiology 276: G951-G957. Mooradian, A., J. E. Morley, A. Levine, W. Prigge, and R. Gebhard. 1986. Abnormal intestinal permeability to sugars in diabetes mellitus. Diabetologia 29: 221-224. Murri, M., I. Leiva, J. M. Gomez-Zumaquero, F. J. Tinahones, F. Cardona, F. Soriguer, and M. I. Queipo-Ortuño. 2013. Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study. BMC Medicine11: 46. Neu, J., C. M. Reverte, A. D. Mackey, K. Liboni, L. M Tuhacek-Tenace, M. Hatch, N. Li, R. A. Caicedo, D. A Schatz, and M. Atkinson. 2005. Changes in intestinal morphology and permeability in the biobreeding rat before the onset of type 1 diabetes. Journal of Pediatric Gastroenterology and Nutrition 40: 589-595. Notkins, A. L., and J. W. Yoon. 1984. Virus-induced diabetes mellitus. Springer New York: 241-247. Ohland, C. L., and W. K. MacNaughton. 2010. Probiotic bacteria and intestinal epithelial barrier function. American Journal of Physiology-Gastrointestinal and Liver Physiology 298: G807-G819. Oikarinen, M., S. Tauriainen, T. Honkanen, S. Oikarinen, K. Vuori, K. Kaukinen, and H. Hyöty. 2008. Detection of enteroviruses in the intestine of type 1 diabetic patients. Clinical and Experimental Immunology 151: 71-75. Paik, S. G., N. Fleischer, and S. I. Shin. 1980. Insulin-dependent diabetes mellitus induced by subdiabetogenic doses of streptozotocin: obligatory role of cell-mediated autoimmune processes. Proceedings of the National Academy of Sciences 77: 6129–6133. Pappu, B. P. and C. Dong. 2007. Measurement of Interleukin‐17. Current Protocols in Immunology: 6-25. Rescigno, M., M. Urbano, B. Valzasina, M. Francolini, G. Rotta, R. Bonasio, F. Granucci, J.-P. Kraehenbuhl, and P. Ricciardi-Castagnoli. 2001. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nature Immunology 2: 361-367. Resta-Lenert, S., and K. Barrett. 2003. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 52: 988-997. Roep, B. O., and M. Peakman. 2012. Antigen targets of type 1 diabetes autoimmunity. Cold Spring Harbor Perspectives in Medicine 2: a007781. Roesch, L. F., G. L. Lorca, G. Casella, A. Giongo, A. Naranjo, A. M. Pionzio, N. Li, V. Mai, C. H. Wasserfall, and D.Schatz. 2009. Culture-independent identification of gut bacteria correlated with the onset of diabetes in a rat model. The ISME Journal 3: 536-548. Sabbah, E., K. Savola, P. Kulmala, R. Veijola, P. Vähäsalo, J. Karjalainen, and M. Knip. 1999. Diabetes-associated autoantibodies in relation to clinical characteristics and natural course in children with newly diagnosed type 1 diabetes. The Journal of Clinical Endocrinology and Metabolism 84: 1534-1539. Savilahti, E., T. Örmälä, T. Saukkonen, U. Sandini‐Pohjavuori, J. M. Kantele, A. Arato, and H. K. Åkerblom. 1999. Jejuna of patients with insulin‐dependent diabetes mellitus (IDDM) show signs of immune activation. Clinical and Experimental Immunology 116: 70-77. Sanz, Y., M. Olivares, Á. Moya-Pérez, and C. Agostoni. 2014. Understanding the role of gut microbiome in metabolic disease risk. Pediatric Research 77: 236-244. Schmidt, S. V., A. C. Nino-Castro, and J. L. Schultze. 2012. Regulatory dendritic cells: there is more than just immune activation. Frontiers in immunology 3. Schultz, M., C. Veltkamp, L. A. Dieleman, W. B. Grenther, P. B. Wyrick, S. L Tonkonogy, and R. B. Sartor. 2002. Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin‐10‐deficient mice. Inflammatory Bowel Diseases 8: 71-80. Serreze, D.V., and P. A. Silveira. 2002. The role of B lymphocytes as key antigen-presenting cells in the development of T cell-mediated autoimmune type 1 diabetes. In B Cell Biology in Autoimmunity. Karger Publishers: 212-227. Shanahan, F. 2010. Probiotics in perspective. Gastroenterology 139: 1808-1812. Shao, S., F. He, Y. Yang, G. Yuan, M. Zhang, and X.Yu. 2012. Th17 cells in type 1 diabetes. Cellular Immunology 280: 16-21. Smelt, M. J., B. J. de Haan, P. A. Bron, I. van Swam, M. Meijerink, J. M. Wells, M. M. Faas, and P. de Vos. 2012. Lb. plantarum, Lb. salivarius, and Lb. lactis attenuate Th2 responses and increase Treg frequencies in healthy mice in a strain dependent manner. PLoS One 7: e47244. Smits, H. H., A. Engering, D. van der Kleij, E. C. de Jong, K. Schipper, T. M. van Capel, B. A. Zaat, M. Yazdanbakhsh, E. A Wierenga,and Y. van Kooyk. 2005. Selective probiotic bacteria induce IL-10–producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell–specific intercellular adhesion molecule 3–grabbing nonintegrin. Journal of Allergy and Clinical Immunology 115: 1260-1267. Sorini, C. and M. Falcone. 2013. Shaping the (auto) immune response in the gut: the role of intestinal immune regulation in the prevention of type 1 diabetes. American Journal of Clinical and Experimental Immunology 2: 156-171. Suarez-Pinzon, W. L., J. G. Mabley, K. Strynadka, R. F. Power, C. Szabó, and A. Rabinovitch. 2001. An inhibitor of inducible nitric oxide synthase and scavenger of peroxynitrite prevents diabetes development in NOD mice. Journal of autoimmunity. 16: 449-455. Turley, S. J., J.-W. Lee, N. Dutton-Swain, D. Mathis, and C. Benoist. 2005. Endocrine self and gut non-self intersect in the pancreatic lymph nodes. Proceedings of the National Academy of Sciences of the United States of America 102: 17729-17733. Tiittanen, M., M. Westerholm‐Ormio, M. Verkasalo, E. Savilahti, and O. Vaarala. 2008. Infiltration of forkhead box P3‐expressing cells in small intestinal mucosa in coeliac disease but not in type 1 diabetes. Clinical and Experimental Immunology 152: 498-507. Ukena, S. N., A. Singh, U. Dringenberg, R. Engelhardt, U. Seidler, W. Hansen, A. Bleich, D. Bruder, A. Franzke, and G. Rogler. 2007. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS one 2: e1308. Vaarala, O. 2011. The gut as a regulator of early inflammation in type 1 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity 18: 241-247. Vaarala, O., M. A. Atkinson, and J. Neu. 2008. The “Perfect storm” for type 1 diabetes the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes 57: 2555-2562. Valladares, R., D. Sankar, N. Li, E. Williams, K.-K. Lai, A. S. Abdelgeliel, C. F. Gonzalez, C. H. Wasserfall, J. Larkin III, and D. Schatz. 2010. Lactobacillus johnsonii N6. 2 mitigates the development of type 1 diabetes in BB-DP rats. PLos ONE 5: e10507. Verge, C. F., R. Gianani, L. Yu, M. Pietropaolo, T. Smith, R. A. Jackson, and G. S. Eisenbarth. 1995. Late progression to diabetes and evidence for chronic β-cell autoimmunity in identical twins of patients with type I diabetes. Diabetes 44: 1176-1179. Wang, L., K. Pino-Lagos, , V. C. de Vries, I. Guleria, , M. H. Sayegh, and R. J. Noelle. 2008. Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+ CD4+ regulatory T cells. Proceedings of the National Academy of Sciences 105: 9331-9336. Wang, Y., I. Kirpich, Y. Liu, Z. Ma, S. Barve, C. J. McClain, and W. Feng. 2011. Lactobacillus rhamnosus GG treatment potentiates intestinal hypoxia-inducible factor, promotes intestinal integrity and ameliorates alcohol-induced liver injury. The American Journal of Pathology 179: 2866-2875. Watanabe, K. and K. Matsuda. 2009 Analysis of intestinal microflora by qPCR and RT-qPCR. Asian Federation of Societies for Lactic Acid Bacteria International Symposium. Singapore. Watts, T., I. Berti, A. Sapone, T. Gerarduzzi, T. Not, R. Zielke, and A. Fasano. 2005. Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats. Proceedings of the National Academy of Sciences of the United States of America 102: 2916-2921. Wei, S. H., Y. P. Chen, and M. J. Chen. 2015. Selecting probiotics with the abilities of enhancing GLP-1 to mitigate the progression of type 1 diabetes in vitro and in vivo. Journal of Functional Foods 18: 473-486. Wen, L., R. E. Ley, P. Y. Volchkov, P. B. Stranges, L. Avanesyan, A. C. Stonebraker, C. Hu, F. S. Wong, G. L. Szot, and J. A. Bluestone. 2008. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 455: 1109-1113. Westerholm-Ormio, M., O. Vaarala, P. Pihkala, J. Ilonen, and E. Savilahti. 2003. Immunologic activity in the small intestinal mucosa of pediatric patients with type 1 diabetes. Diabetes 52: 2287-2295. Wu, K. K., and Y. Huan. 2007. Diabetic atherosclerosis mouse models. Atherosclerosis 191: 241-249. Yadav, H., S. Jain, and P. R. Sinha. 2007. Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition 23(1): 62-68. Yadav, H., J. H. Lee, J. Lloyd, P. Walter, and S. G. Rane. 2013. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. Journal of Biological Chemistry 288: 25088-25097. Yoon, J.-W., M. Austin, T. Onodera, and A. L.Notkins. 1979. Virus-induced diabetes mellitus: isolation of a virus from the pancreas of a child with diabetic ketoacidosis. New England Journal of Medicine 300: 1173-1179. Yoon, J. W., T. Morishima, P. R. McClintock, M. Austin, and A. L. Notkins. 1984. Virus-induced diabetes mellitus: mengovirus infects pancreatic beta cells in strains of mice resistant to the diabetogenic effect of encephalomyocarditis virus. Journal of Virology 50: 684-690. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/67015 | - |
dc.description.abstract | 本研究於體外試驗中,將模擬人類腸道上皮細胞之Caco 2單層膜細胞與活菌Lb. kefiri K進行共培養後,發現細胞緊密結合蛋白基因OCLN表現量顯著上升(p < 0.05)。此外,不管是熱致死處理或是活菌Lb. kefiri K皆可以藉由提高小鼠骨髓分離之樹突細胞表面分子MHC classⅡ、CD40、CD86之表現量進而使其成熟。從這些結果推測Lb. kefiri K可能透過提高腸道黏膜屏障及調節免疫反應進而影響第一型糖尿病(T1D)。
在本研究第一次動物試驗方面,在連續注射5天STZ誘導8週齡C57BL/6 小鼠T1D前,連續給予7天菌株K(此為第0週),其空腹血糖值於第1週開始顯著高於STZ組,而在第8週K組小鼠口服糖耐量曲線下面積會顯著高於STZ組(p < 0.05),這些糖尿病相關症狀的加劇與先前文獻並不一致。有趣的是,第一次試驗小鼠血清中GLP-1及胰島素之濃度結果卻與先前文獻相似,而迴腸緊密結合蛋白之表現量在各組間皆無顯著差異,在培氏斑及腸繫膜淋巴結中,發現給予了活菌之組別CD4+ T細胞之比率顯著降低(p < 0.05)。造成此次試驗結果與先前文獻不一致之原因,我們推測可能包含了菌株的變異、實驗鼠之週齡及個體差異等因素。 為了進一步探討這些因素是否會影響試驗結果,本研究重新活化菌株K並同時使用5及8週齡小鼠進行第二次試驗。試驗結果顯示給予5及8週齡誘發T1D小鼠菌株K皆可以減緩T1D相關症狀包含空腹血糖值、口服糖耐量及其曲線下面積,暗示週齡之不同並非第一次試驗與先前文獻不一致之因素。此外,第二次動物試驗中發現給予菌株K之組別,在三個淋巴相關組織中,CD4+ T細胞之比例相對於控制組並無顯著差異。 綜上述,我們推測兩次體內試驗結果不同可能與菌株重新活化相關,而是否兩次使用之菌株有所差異進而造成T1D病程發展不同,則需要更進一步之探討。 | zh_TW |
dc.description.abstract | In the present study, we investigated the possible mechanisms of Lb. kefiri K involving in its ameliorating hyperglycemia in vitro and in vivo. In vitro, the human epithelial Caco 2 cell monolayer was co-cultured with live or heat-killed Lb. kefiri K. The gene expression of occludin, a tight junction protein, was upregulated after treatment with live Lb. kefiri K. Additionally, Lb. kefiri K also accelerated dendritic cells (DC) maturation by modulating the expression of MHC classⅡ, CD40 and CD86, the surface markers on murine bone marrow dendritic cells (BMDC). The in-vitro results suggested that the possible mechanisms of Lb. kefiri K to ameliorate hyperglycemia might involve in enhancing intestinal integrity and modulating immune response.
We further investigated the mechanisms in vivo. After 1-week administration of 108 CFU Lb. kefiri K per mouse daily, eight-week-old male C57BL/6 mice were induced type 1 diabetes (T1D) by multiple low dosage of STZ. The Lb. kefiri K treatment was continued for nine weeks. Results indicated that no significant difference was found on gene expression of tight junction protein among the groups. The Lb. kefiri K treated group showed the significantly higher fasting blood glucose level and lower percentage of CD4+ T cells in Peyer’s patches and mesenteric lymph node (p < 0.05) than the STZ group. Lb. kefiri K treatment also indicated to increase GLP-1 level in serum (p < 0.1). Interestingly, the in-vivo findings were inconsistence with our previous study. The differences might be due to the age of mice, strain and individual differences. To further investigate possible factors involved, five and eight-week-old male C57BL/6 mice were used in the 2nd experiment. In addition, the strain K also be re-activated from stock. Results indicated that administration of live Lb. kefiri K ameliorated T1D associated symptoms including fasting blood glucose, oral glucose tolerance test and the area under curve on both five and eight-week-old mice (p < 0.05). It demonstrated that age might not be the factor influencing the 1st in vivo result. Besides, there was no significant difference between CD4+ T cell percentages in Peyer’s patches and mesenteric lymph node of each group. Above all, the different results in vivo might be due to the re-activated strain K. There might be difference between cultures of strain K used in two experiments. However, further study is necessary to investigate possible reasons. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T01:17:18Z (GMT). No. of bitstreams: 1 ntu-106-R04626019-1.pdf: 4035267 bytes, checksum: 6cf7a3629a79c8d65b6e8b14f8f881ce (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 目錄
壹、文獻探討 1 第一節:簡介 1 一、糖尿病(diabetes) 1 二、第一型糖尿病之病因 3 第二節:益生菌對糖尿病之影響 9 一、益生菌 9 二、益生菌與糖尿病 9 三、益生菌影響糖尿病之可能機制 10 小結 16 貳、材料與方法 17 第一節:藉由體外試驗探討Lb. kefiri K減緩T1D之機制 17 一、實驗材料 17 二、試驗方法 18 第二節:藉由動物實驗探討Lb. kefiri預防T1D之效果及可能機制 26 一、實驗材料 26 二、試驗方法 26 統計分析 35 參、結果 36 第一節:藉由體外試驗探討Lb. kefiri K影響T1D之機制 36 一、探討Lb. kefiri K對腸道上皮完整性之影響 36 二、探討Lb. kefiri K對未成熟樹突細胞之調節能力 36 第二節:藉由動物實驗探討Lb. kefiri 影響T1D之機制 39 一、Lb. kefiri K對STZ誘導T1D小鼠之糖尿病症狀評估 39 二、Lb. kefiri K對STZ誘導T1D小鼠作用之可能機制 40 肆、討論 72 第一節:藉由體外試驗探討Lb. kefiri K影響T1D之機制 72 一、菌株K對於腸道黏膜完整性之影響 72 二、菌株K之免疫調節能力 73 第二節:藉由動物實驗探討Lb. kefiri K影響T1D之機制 74 伍、結論 80 陸、參考文獻 81 | |
dc.language.iso | zh-TW | |
dc.title | 探討Lactobacillus kefiri K影響第一型糖尿病之可能機制 | zh_TW |
dc.title | Investigation of possible mechanism of Lactobacillus kefiri K on its affecting type 1 diabetes | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 陳彥伯,曾浩洋,劉?睿,潘子明 | |
dc.subject.keyword | 乳酸菌,免疫調節,腸道黏膜屏障,糖尿病,升糖素類似胜?, | zh_TW |
dc.subject.keyword | lactic acid bacteria,immune-regulatory effect,gut mucosal barrier function,diabetes,glucagon-like peptide-1, | en |
dc.relation.page | 94 | |
dc.identifier.doi | 10.6342/NTU201703147 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2017-08-14 | |
dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
dc.contributor.author-dept | 動物科學技術學研究所 | zh_TW |
顯示於系所單位: | 動物科學技術學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 3.94 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。